Current and historical daily PE Ratio for Tonix Pharmaceuticals Holding Corp (
STU:TPM0
) from 2014 to Jun 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Tonix Pharmaceuticals Holding stock (STU:TPM0) PE ratio as of Jun 19 2024 is 0.
More Details
Tonix Pharmaceuticals Holding Corp (STU:TPM0) PE Ratio (TTM) Chart
Tonix Pharmaceuticals Holding Corp (STU:TPM0) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1299
- 1
- 2
- 3
- 4
- 5
- 6
- 15
Tonix Pharmaceuticals Holding PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-19 | At Loss | 2024-04-17 | At Loss |
2024-06-18 | At Loss | 2024-04-16 | At Loss |
2024-06-17 | At Loss | 2024-04-15 | At Loss |
2024-06-14 | At Loss | 2024-04-12 | At Loss |
2024-06-13 | At Loss | 2024-04-11 | At Loss |
2024-06-12 | At Loss | 2024-04-10 | At Loss |
2024-06-11 | At Loss | 2024-04-09 | At Loss |
2024-06-10 | At Loss | 2024-04-08 | At Loss |
2024-06-07 | At Loss | 2024-04-05 | At Loss |
2024-06-06 | At Loss | 2024-04-04 | At Loss |
2024-06-05 | At Loss | 2024-04-03 | At Loss |
2024-06-04 | At Loss | 2024-04-02 | At Loss |
2024-06-03 | At Loss | 2024-04-01 | At Loss |
2024-05-31 | At Loss | 2024-03-29 | At Loss |
2024-05-30 | At Loss | 2024-03-28 | At Loss |
2024-05-29 | At Loss | 2024-03-27 | At Loss |
2024-05-28 | At Loss | 2024-03-26 | At Loss |
2024-05-27 | At Loss | 2024-03-25 | At Loss |
2024-05-24 | At Loss | 2024-03-22 | At Loss |
2024-05-23 | At Loss | 2024-03-21 | At Loss |
2024-05-22 | At Loss | 2024-03-20 | At Loss |
2024-05-21 | At Loss | 2024-03-19 | At Loss |
2024-05-20 | At Loss | 2024-03-18 | At Loss |
2024-05-17 | At Loss | 2024-03-15 | At Loss |
2024-05-16 | At Loss | 2024-03-14 | At Loss |
2024-05-15 | At Loss | 2024-03-13 | At Loss |
2024-05-14 | At Loss | 2024-03-12 | At Loss |
2024-05-13 | At Loss | 2024-03-11 | At Loss |
2024-05-10 | At Loss | 2024-03-08 | At Loss |
2024-05-09 | At Loss | 2024-03-07 | At Loss |
2024-05-08 | At Loss | 2024-03-06 | At Loss |
2024-05-07 | At Loss | 2024-03-05 | At Loss |
2024-05-06 | At Loss | 2024-03-04 | At Loss |
2024-05-03 | At Loss | 2024-03-01 | At Loss |
2024-05-02 | At Loss | 2024-02-29 | At Loss |
2024-05-01 | At Loss | 2024-02-28 | At Loss |
2024-04-30 | At Loss | 2024-02-27 | At Loss |
2024-04-29 | At Loss | 2024-02-26 | At Loss |
2024-04-26 | At Loss | 2024-02-23 | At Loss |
2024-04-25 | At Loss | 2024-02-22 | At Loss |
2024-04-24 | At Loss | 2024-02-21 | At Loss |
2024-04-23 | At Loss | 2024-02-20 | At Loss |
2024-04-22 | At Loss | 2024-02-19 | At Loss |
2024-04-19 | At Loss | 2024-02-16 | At Loss |
2024-04-18 | At Loss | 2024-02-15 | At Loss |
Tonix Pharmaceuticals Holding Corp (STU:TPM0) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Tonix Pharmaceuticals Holding Corp Tonix Pharmaceuticals Holding Corp logo](https://static.gurufocus.com/logos/0C000018X6.png?14)
Tonix Pharmaceuticals Holding Corp
NAICS : 325412
SIC : 2834
ISIN : US8902604094
Description
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.